Dynavax Technologies (NASDAQ:DVAX) Shares Pass Above Two Hundred Day Moving Average – What’s Next?

Dynavax Technologies Co. (NASDAQ:DVAX) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.62 and traded as high as $12.87. Dynavax Technologies shares last traded at $12.62, with a volume of 5,449,688 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Stock Up 0.1 %

The company has a market capitalization of $1.66 billion, a PE ratio of 97.16 and a beta of 1.34. The stock has a 50-day moving average of $12.74 and a 200 day moving average of $11.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of DVAX. Nordea Investment Management AB raised its stake in shares of Dynavax Technologies by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after acquiring an additional 232,690 shares in the last quarter. GAMMA Investing LLC grew its position in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares during the last quarter. Franklin Resources Inc. increased its stake in Dynavax Technologies by 5.7% in the 3rd quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company’s stock worth $862,000 after purchasing an additional 4,459 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Dynavax Technologies in the third quarter valued at approximately $89,000. Finally, Sanctuary Advisors LLC increased its stake in shares of Dynavax Technologies by 9.1% in the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 1,484 shares during the period. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.